{
  "id": 1697994,
  "title": "Amylyx reports Phase 3 win for GLP-1 antagonist avexitide in post-bariatric hypoglycemia",
  "url": "https://urgent.news/2026/08/18/amylyx-reports-phase-3-win-for-glp-1-antagonist-avexitide-in-post",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-18T11:01:54.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/amylyx-reports-phase-3-win-for-glp-1-antagonist-avexitide-in-post-bariatric-hypoglycemia/"
  },
  "original_language": "en",
  "account": null,
  "summary": "After a turbulent few years researching ALS, Amylyx Pharmaceuticals said it has notched a success in its attempt to rebuild as a GLP-1 biotech. A Phase 3 study for avexitide, a GLP-1 receptor antagonist, hit ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}